| Symbol | CKDXF |
|---|---|
| Name | OPTHEA LIMITED |
| Sector | HEALTH CARE |
| Region | Oceania |
| Industry | - |
| Address | 10286 United States NY c/o The Bank Of New York Mellon One Wall Street |
| Telephone | 61 3 9826 0399 |
| Fax | — |
| — | |
| Website | http://www.opthea.com |
| Incorporation | AU |
| Incorporated On | 1984 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC;NASDAQ;Pink Limited |
| Auditor | Deloitte Touche Tohmatsu; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | 0001815620 |
| Description | Opthea Limited is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases. Optheas lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD). Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients. Additional info from OTC: Additional info from NASDAQ: Additional info from Pink Limited: |
Pink Current symbol attribute type Security_Name was changed. Previous value: -. New value: OPTHEA LTD ORD.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: OPTHEA LTD ORD.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04757636 | OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) | Phase3 | Neovascular Age-related Macular Degeneration | Terminated | 2021-03-12 | 2025-03-31 | ClinicalTrials.gov |
| NCT04757610 | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) | Phase3 | Neovascular Age-related Macular Degeneration | Terminated | 2021-03-12 | 2025-03-31 | ClinicalTrials.gov |
| NCT03397264 | A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macula… | Phase1 | Diabetic Macular Edema | Completed | 2018-01-16 | 2020-06-11 | ClinicalTrials.gov |
| NCT03345082 | A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD | Phase2 | Neovascular Age-related Macular Degeneration | Completed | 2017-11-06 | 2019-05-14 | ClinicalTrials.gov |
| NCT02543229 | Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 W… | Phase1 | Eye Diseases | Completed | 2015-07-01 | 2017-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Lucentis™ | Other | Phase PHASE1 | Eye Diseases | COMPLETED | NCT02543229 |
| OPT-302 | Other | Phase PHASE1 | Eye Diseases | COMPLETED | NCT02543229 |
| sham intravitreal injection | Other | Phase PHASE2 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03345082 |
| ranibizumab | Other | Phase PHASE2 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03345082 |
| OPT-302 | Other | Phase PHASE2 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03345082 |
| Sham intravitreal injection | Other | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT03397264 |
| OPT-302 | Other | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT03397264 |
| Aflibercept | Other | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT03397264 |
| Sham | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757610 |
| 0.5 mg ranibizumab | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757610 |
| 2.0 mg OPT-302 | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757610 |
| Sham | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757636 |
| 2.0 aflibercept | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757636 |
| 2.0 mg OPT-302 | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757636 |
| 2.0 aflibercept | BIOLOGICAL | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757636 |
| Sham | PROCEDURE | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757636 |
| 0.5 mg ranibizumab | BIOLOGICAL | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757610 |
| 2.0 mg OPT-302 | BIOLOGICAL | Phase PHASE3 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04757636 |
| Sham intravitreal injection | OTHER | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT03397264 |
| Aflibercept | BIOLOGICAL | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT03397264 |
| sham intravitreal injection | OTHER | Phase PHASE2 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03345082 |
| ranibizumab | BIOLOGICAL | Phase PHASE2 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03345082 |
| Lucentis™ | DRUG | Phase PHASE1 | Eye Diseases | COMPLETED | NCT02543229 |
| OPT-302 | BIOLOGICAL | Phase PHASE1 | Diabetic Macular Edema | COMPLETED | NCT03397264 |